Key Highlights

  • Management lowered its 2026 Research and Development Revenue outlook to about USD 13 million from about USD 18.5 million, citing the end of the MTEC program and the timing of BARDA-reimbursed work.
  • Research and development revenue for the third quarter was USD 2.9 million, down 24.7% from USD 3.8 million, with BARDA revenue of USD 2.7 million against USD 3.4 million a year earlier.
  • Net loss was USD 3.7 million, or USD 0.11 per share, against USD 3.6 million, or USD 0.13, while adjusted EBITDA, a non-GAAP measure, was a loss of USD 3.7 million versus USD 3.1 million.
  • Cash was USD 11.2 million at September 30, 2026, down from USD 15.4 million at year end, and the Avenue Loan Facility is fully drawn at USD 15 million.

Guidance Cut Reflects Narrower BARDA Scope and the End of MTEC

Spectral AI (NASDAQ:MDAI) discussed its third-quarter 2026 results on a call on November 10, 2026, and said it expects to file its Quarterly Report on or before November 16. The company develops DeepView AI, an artificial intelligence system that assesses burn wounds. Management said the new outlook of about USD 13 million replaces about USD 18.5 million, because the MTEC handheld program is complete with no more contracts expected in 2026 and because BARDA-reimbursed development work moves revenue into later periods within the existing contract term. The guidance excludes DeepView AI device sales and any new or extended government awards.

Cost Sharing Squeezes Gross Margin to 27.2%

BARDA has supported DeepView AI with USD 250 million of non-dilutive funding, the chief financial officer said, leading to FDA de novo authorization in May. In June the company moved to a follow-on phase in which BARDA reimburses part of development costs and the company funds the rest. That cost share is recorded in cost of revenue, so gross margin fell to 27.2% from 42.7%. Other U.S. government revenue was USD 0.1 million against USD 0.4 million. Total operating expenses fell 4% to USD 4.7 million as general and administrative expense dropped to USD 2.3 million on lower legal fees, while research and development rose to USD 2.0 million on a UK label expansion study.

Commercial Launch Steps and the Cash Runway

Management said it began Manufacturing the first 30 DeepView AI systems for BARDA-supported deployments at US burn centers, and called first commercial sales an achievable goal for 2026. A UKCA approval update is now expected in early 2027, later than the year-end target previously expected. A Medicare add-on payment application is pending, with a decision expected by August 2027. The company said it has about USD 90 million of additional non-dilutive BARDA funding available. Other income included a USD 0.8 million Warrant Fair Value gain, offset by USD 0.6 million of net interest expense. Cash used in operations was USD 10.5 million over nine months, and management called the company well capitalized for its commercial priorities.

Where Things Stand

The outlook was cut because government-funded development revenue is shrinking before commercial sales have started. Spectral AI (NASDAQ:MDAI) lowered 2026 research and development revenue guidance by about USD 5.5 million (calculated), reported a third-quarter loss of USD 3.7 million and holds USD 11.2 million of cash. The offsets are a manufacturing start for 30 systems, a pending Medicare payment decision and access to more BARDA funding. The call gave no commercial revenue guidance, no sales figures and no share price reaction. Watch first device deliveries, the TNT study start in December, the UKCA approval in early 2027 and the cash balance.